Comment
. 2005 May;5(5):1164; author reply 1165-6.
doi: 10.1111/j.1600-6143.2005.00778.x.
Mycophenolate sodium does not reduce the incidence of GI adverse events compared with mycophenolate mofetil
- PMID: 15816903
- DOI: 10.1111/j.1600-6143.2005.00778.x
Item in Clipboard
Comment
Mycophenolate sodium does not reduce the incidence of GI adverse events compared with mycophenolate mofetil
Am J Transplant.
2005 May.
Free article
No abstract available
Comment on
-
Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients.Am J Transplant. 2004 Feb;4(2):231-6. doi: 10.1046/j.1600-6143.2003.00337.x. Am J Transplant. 2004. PMID: 14974944 Clinical Trial.
-
Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients: results of a 1-year study.Am J Transplant. 2004 Feb;4(2):237-43. doi: 10.1046/j.1600-6143.2003.00321.x. Am J Transplant. 2004. PMID: 14974945 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
